Scholars Central

Research articlePublished 28 Feb 2017

Double Expression of Epidermal Growth Factor Receptor and N-Glycolyl GM3 Ganglioside in Human Malignant Tumors: A Study in Four Different Clinical Scenarios

Authors: Rancés Blanco, Mercedes Cedeño, Charles E Rengifo, Damián Blanco, Milagros Frometa1 Elizabeth Domínguez, Mayra Ramos- Suzarte, Adriana Carr, Enrique Rengifo

Center of Molecular Immunology, Atabey, Playa, Havana, Cuba; Department of Pathology, National Institute of Oncology and Radiobiology, Vedado, Plaza de la Revolution, Havana, Cuba; Department of Cell Biology and Tissues Banking, National Institute of Oncology and Radiobiology, Vedado, Plaza de la Revolution, Havana, Cuba; Laboratory of Biochemistry, Center of Molecular Immunology, Atabey, Playa, Havana, Cuba; Clinical Trials Direction, Center of Molecular Immunology, Atabey, Playa, Havana, Cuba; System Biology Direction, Center of Molecular Immunology, Atabey, Playa, Havana, Cuba

Advances in Molecular Diagnostics

Volume 2 · Issue 1 · Pages 1–6

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The interaction between the epidermal growth factor receptor (EGFR) and N-glycolyl GM3 ganglioside (NeuGcGM3) and its contribution to the progression of tumors have been previously described. However, studies concerning to the double expression of EGFR and NeuGcGM3 in human tissues are scarce. Here, it was evaluated by immunohistochemistry the dual expression of EGFR and NeuGcGM3 in 153 samples of malignant tissues grouped as follow: primary tumors, metastasis, conventionally pre-treated samples and recurrent diseases. The presence of both molecules was evidenced in 60/101 (59.4%) and 18/26 (69.2%) of untreated primary tumors and metastasis, respectively. Remarkably, the dual of EGFR and NeuGcGM3 was statistically significant increase in high grade astrocytoma (22/31) when compared with low-grade astrocytomas (0/14) (p=0.000; Chi-square Test). In this type of samples, the tissue expression of EGFR was observed as a finely granular precipitate located in the plasmatic membrane of malignant cells, while NeuGcGM3 was located in the cell membrane but also in the cytoplasm of tumour cells. The double expression of these tissue antigens was detected in 14/20 (70.0%) of cases that received standard chemotherapy and/or radiotherapy schemes after the surgical removal of tumors. Interestingly, the expression pattern of EGFR and NeuGcGM3 after conventional treatment was similar to those observed in the rest of non-treated samples. Moreover, preliminary data revealed the dual appearance of these molecules in 4/6 (66.7%) of tumor recurrences. All these facts could support the potential design of combined immunotherapy schemes targeting simultaneously both EGFR and NeuGcGM3 in these clinical situations.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Advances in Molecular Diagnostics.

All its articles

Short communication · 9 Feb 2017

Viral Coinfections

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalAdvances in Molecular Diagnostics
  • SubjectGenetics & Molecular Biology
  • SubjectPathology & Lab Medicine
  • BylineArticles whose byline prints “Rancés Blanco”
  • BylineArticles whose byline prints “Mercedes Cedeño”
  • BylineArticles whose byline prints “Charles E Rengifo”
  • BylineArticles whose byline prints “Damián Blanco”
  • BylineArticles whose byline prints “Milagros Frometa1 Elizabeth Domínguez”
  • BylineArticles whose byline prints “Mayra Ramos- Suzarte”
  • BylineArticles whose byline prints “Adriana Carr”
  • BylineArticles whose byline prints “Enrique Rengifo”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels